$APHP
American Picture House Corp Stock $aphp

$aphp Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000149315224011751 Filed on March 28, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$23.00K	$31.95K	$201.1K
YoY Change	-86.4%	-90.77%	-56.4%
Cost Of Revenue		$0.00	$36.70K
YoY Change		-100.0%	-72.14%
Gross Profit	$23.00K	$31.95K	$164.4K
YoY Change	-82.63%	-85.2%	-50.11%
Gross Profit Margin	100.0%	100.0%	81.75%
Selling, General & Admin	$1.516M	$443.7K	$1.518M
YoY Change		349.74%	270.8%
% of Gross Profit	6590.04%	1388.64%	923.38%
Research & Development		$2.610K	$11.42K
YoY Change
% of Gross Profit		8.17%	6.95%
Depreciation & Amortization	$750.00	$750.00	$1.000K
YoY Change
% of Gross Profit	3.26%	2.35%	0.61%
Operating Expenses	$1.516M	$446.3K	$1.529M
YoY Change	725.64%	352.39%	273.59%
Operating Profit	-$1.493M	-$414.3K	-$1.365M
YoY Change	2816.23%	-453.46%	1609.3%
Interest Expense	$3.185K	$2.540K	$6.227K
YoY Change	68.7%	-443.24%	-205.19%
% of Operating Profit
Other Income/Expense, Net	-$3.083K		-$1.609K
YoY Change	168.79%		-72.81%
Pretax Income	-$1.496M	-$411.8K	-$1.366M
YoY Change	2758.21%	-453.51%	1493.19%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$1.496M	-$411.8K	-$1.400M
YoY Change	2758.26%	-453.51%	1532.46%
Net Earnings / Revenue	-6503.44%	-1288.89%	-696.31%
Basic Earnings Per Share	-$0.01		-$0.01
Diluted Earnings Per Share	-$0.01	$0.00	-$0.01
COMMON SHARES
Basic Shares Outstanding	109.9M shares	107.7M shares	104.1M shares
Diluted Shares Outstanding	109.9M shares		104.1M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$25.13K	$204.0K	$204.0K
YoY Change			546.09%
Cash & Equivalents	$25.13K	$204.0K
Short-Term Investments
Other Short-Term Assets	$13.37K	$29.19K	$29.19K
YoY Change			-11.17%
Inventory
Prepaid Expenses	$13.37K	$29.19K
Receivables	$51.78K	$31.95K	$33.30K
Other Receivables	$0.00		$0.00
Total Short-Term Assets	$90.89K	$266.5K	$266.5K
YoY Change		-34.98%	-34.98%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles	$74.11K	$71.86K
YoY Change
Long-Term Investments
YoY Change
Other Assets	$200.4K	$210.6K	$210.6K
YoY Change			73.56%
Total Long-Term Assets	$494.5K	$282.5K	$282.5K
YoY Change		132.79%	132.8%
TOTAL ASSETS
Total Short-Term Assets	$90.89K	$266.5K	$266.5K
Total Long-Term Assets	$494.5K	$282.5K	$282.5K
Total Assets	$585.4K	$549.0K	$549.0K
YoY Change		3.35%	3.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$48.71K	$90.38K	$90.38K
YoY Change			-66.98%
Accrued Expenses	$12.53K	$11.58K	$11.58K
YoY Change		-88.97%	12.54%
Deferred Revenue
YoY Change
Short-Term Debt	$250.0K	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$361.2K	$102.0K	$102.0K
YoY Change		-77.29%	-77.29%
LONG-TERM LIABILITIES
Long-Term Debt	$149.9K	$149.9K	$149.9K
YoY Change			0.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$149.9K	$149.9K	$149.9K
YoY Change			0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$361.2K	$102.0K	$102.0K
Total Long-Term Liabilities	$149.9K	$149.9K	$149.9K
Total Liabilities	$511.1K	$251.9K	$251.9K
YoY Change		-57.95%	-57.95%
SHAREHOLDERS EQUITY
Retained Earnings	-$6.518M	-$5.000M
YoY Change		36.78%
Common Stock	$471.6K	$471.6K
YoY Change		0.19%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$74.27K	$297.1K	$297.1K
YoY Change
Total Liabilities & Shareholders Equity	$585.4K	$549.0K	$549.0K
YoY Change		3.35%	3.36%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$1.496M	-$411.8K	-$1.400M
YoY Change	2758.26%	-453.51%	1532.46%
Depreciation, Depletion And Amortization	$750.00	$750.00	$1.000K
YoY Change
Cash From Operating Activities	-$436.1K	-$416.4K	-$1.133M
YoY Change	235.65%	-8201.75%	-22148.52%
INVESTING ACTIVITIES
Capital Expenditures	$3.000K	$63.86K	$72.86K
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$4.770K	-$52.13K	-$89.28K
YoY Change		-57.05%	-26.43%
Cash From Investing Activities	-$7.770K	-$116.0K	-$162.1K
YoY Change	-22.42%	-4.42%	33.6%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$1.468M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$265.0K	205.0K	$1.468M
YoY Change	112.0%	340.84%	3056.63%
NET CHANGE
Cash From Operating Activities	-$436.1K	-416.4K	-$1.133M
Cash From Investing Activities	-$7.770K	-116.0K	-$162.1K
Cash From Financing Activities	$265.0K	205.0K	$1.468M
Net Change In Cash	-$178.8K	-327.4K	$172.4K
YoY Change	1097.57%	369.64%	-347.27%
FREE CASH FLOW
Cash From Operating Activities	-$436.1K	-$416.4K	-$1.133M
Capital Expenditures	$3.000K	$63.86K	$72.86K
Free Cash Flow	-$439.1K	-$480.3K	-$1.206M
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001771995
CY2023Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent		usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill		usd
CY2023Q4	us-gaap	Notes And Loans Receivable Net Noncurrent NotesAndLoansReceivableNetNoncurrent		usd
CY2022Q4	us-gaap	Notes And Loans Receivable Net Noncurrent NotesAndLoansReceivableNetNoncurrent		usd
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense		usd
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense		usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	APHP	Reserve For Uncollectible Receivable ReserveForUncollectibleReceivable		usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets		usd
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets		usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2022	APHP	Conversion Of Accrued Expenses Into Options To Purchase Common Stock ConversionOfAccruedExpensesIntoOptionsToPurchaseCommonStock		usd
CY2023	APHP	Conversion Of Note Payable To Related Parties And Accrued Interest To Common Stock ConversionOfNotePayableToRelatedPartiesAndAccruedInterestToCommonStock		usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Remaining Amortization Period1 FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1	P3Y
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent		usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross		usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization		usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet		usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit		usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit		usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount		usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount		usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Public Float EntityPublicFloat	23327571	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	109865991	shares
CY2023	dei	Auditor Name AuditorName	BF Borgers CPA PC
CY2023	dei	Auditor Firm AuditorFirmId	5041
CY2023	dei	Auditor Location AuditorLocation	Lakewood, CO
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	203971	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	31573	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	31948	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	344924	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	29185	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	32862	usd
CY2022Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	347	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	266453	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	409776	usd
CY2023Q4	APHP	Produced And Licensed Content Costs ProducedAndLicensedContentCosts	210633	usd
CY2022Q4	APHP	Produced And Licensed Content Costs ProducedAndLicensedContentCosts	121355	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	71864	usd
CY2023Q4	us-gaap	Allowance For Notes And Loans Receivable Current AllowanceForNotesAndLoansReceivableCurrent	366387	usd
CY2022Q4	us-gaap	Allowance For Notes And Loans Receivable Current AllowanceForNotesAndLoansReceivableCurrent	366387	usd
CY2023Q4	us-gaap	Assets Assets	548950	usd
CY2022Q4	us-gaap	Assets Assets	531131	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	273699	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	35000	usd
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent	11580	usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	10288	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	101957	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	448987	usd
CY2023Q4	APHP	Economic Injury Disaster Loan Noncurrent EconomicInjuryDisasterLoanNoncurrent	149900	usd
CY2022Q4	APHP	Economic Injury Disaster Loan Noncurrent EconomicInjuryDisasterLoanNoncurrent	149900	usd
CY2023Q4	us-gaap	Liabilities Liabilities	251857	usd
CY2022Q4	us-gaap	Liabilities Liabilities	598887	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	109790991	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	109790991	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	100735159	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	100735159	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	471569	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	470673	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	3829	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	3829	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	3829	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	3829	shares
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	4847220	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	3116949	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-5021696	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	344924	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-3677	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	24562	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-3655378	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	297093	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-67756	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	548950	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	531131	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	461174	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	131722	usd
CY2022	us-gaap	Gross Profit GrossProfit	329452	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	409290	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11416	usd
CY2023	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	6119	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	1529067	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	409290	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-1364709	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-79838	usd
CY2023	us-gaap	Interest And Other Income InterestAndOtherIncome	4618	usd
CY2022	us-gaap	Interest And Other Income InterestAndOtherIncome	2077	usd
CY2023	us-gaap	Interest Expense InterestExpense	6227	usd
CY2022	us-gaap	Interest Expense InterestExpense	7995	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1609	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5918	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1366318	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-85756	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-1366318	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-85756	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	98485159	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	98485159	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-307000	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	300000	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	25000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-85756	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-67756	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-67756	usd
CY2023	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	105000	usd
CY2023	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	1160221	shares
CY2023	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	105000	usd
CY2023	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	158333	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-1366318	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	297093	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	297093	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-1366318	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-85756	usd
CY2023	APHP	Reserve For Uncollectible Receivable ReserveForUncollectibleReceivable	193932	usd
CY2023	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	158333	usd
CY2022	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	25000	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-119044	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	31948	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	344924	usd
CY2023	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-347	usd
CY2022	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	347	usd
CY2023	us-gaap	Increase Decrease In Due From Related Parties Current IncreaseDecreaseInDueFromRelatedPartiesCurrent	1279	usd
CY2022	us-gaap	Increase Decrease In Due From Related Parties Current IncreaseDecreaseInDueFromRelatedPartiesCurrent	70	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-78322	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	264884	usd
CY2023	us-gaap	Increase Decrease In Due To Related Parties Current IncreaseDecreaseInDueToRelatedPartiesCurrent	-130000	usd
CY2022	us-gaap	Increase Decrease In Due To Related Parties Current IncreaseDecreaseInDueToRelatedPartiesCurrent	130000	usd
CY2023	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-35000	usd
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	35000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1133294	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	5139	usd
CY2023	APHP	Payments To Produced And Licensed Costs PaymentsToProducedAndLicensedCosts	89278	usd
CY2022	APHP	Payments To Produced And Licensed Costs PaymentsToProducedAndLicensedCosts	121355	usd
CY2023	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	72864	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-162142	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-121355	usd
CY2023	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	178500	usd
CY2022	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	115260	usd
CY2023	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	178500	usd
CY2022	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	68760	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1467834	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1467834	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	46500	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	172398	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-69716	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	31573	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	101289	usd
CY2023	APHP	Conversion Of Accrued Expenses Into Options To Purchase Common Stock ConversionOfAccruedExpensesIntoOptionsToPurchaseCommonStock	105000	usd
CY2022	APHP	Conversion Of Note Payable To Related Parties And Accrued Interest To Common Stock ConversionOfNotePayableToRelatedPartiesAndAccruedInterestToCommonStock	300000	usd
CY2023	us-gaap	Stock Issued1 StockIssued1	158333	usd
CY2022	us-gaap	Stock Issued1 StockIssued1	25000	usd
CY2023Q4	APHP	Working Capital WorkingCapital	164496	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-5021696	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_845_eus-gaap--UseOfEstimates_zJmCasccHfM7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_868_zDvzs2lnT0f6">Use of Estimates</span></span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to income taxes and contingencies. The Company bases its estimates on historical experience, known or expected trends, and various other assumptions that are believed to be reasonable given the quality of information available as of the date of these financial statements. The results of these assumptions provide the basis for making estimates about the carrying amount of assets and liabilities that are not readily apparent from other sources. Actual results could differ from these estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2023Q4	APHP	Cash Sipc Insured Amount CashSIPCInsuredAmount	500000	usd
CY2023Q4	us-gaap	Allowance For Uncollectible Customers Liability For Acceptances AllowanceForUncollectibleCustomersLiabilityForAcceptances	193932	usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	29185	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	32862	usd
CY2023Q4	APHP	Filims In Development And Preproduction Stage FilimsInDevelopmentAndPreproductionStage	210633	usd
CY2023Q4	APHP	Produced And Licensed Content Costs ProducedAndLicensedContentCosts	210633	usd
CY2022Q4	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	130000	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	35000	usd
CY2023	us-gaap	Revenue Recognition Services Licensing Fees RevenueRecognitionServicesLicensingFees	<p id="xdx_84E_eus-gaap--RevenueRecognitionServicesLicensingFees_zLTQ6UlmdEbi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline"><span id="xdx_86D_zMyTVzcJlqtf">Revenues and Costs from Services and Products</span></span></i></b> – Historically, Company’s revenue comes from contracts with customers for consulting services and from the licensing and distribution of film and other entertainment rights. The consulting services typically relate to development of business strategy and monetization of intellectual property rights. The Company accounts for a contract with a customer when there is an enforceable contract between the Company and the customer, the rights of the party are identified, the contract has economic substance, and collectability of the contract is considered probable. Historically, the term of these consulting agreements has been approximately three to six months in duration. The Company’s revenue is measured based on considerations specified in the contract with each customer. Accounting Standards Codification (“ASC”) 606 allows for adoption of an “as invoiced” practical expedient that allows companies to recognize revenue in the amount to which the entity has a right to invoice when they have a right to consideration from a customer in an amount that corresponds directly with the value to the customer of the entity’s performance completed to date. The Company has elected to adopt this practical expedient with regards to its consulting services revenue. All 2023 revenues were derived from a single customer. Approximately <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zEKN7oiwsdYj" title="Concentration risk, percentage">13</span>%, <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zerQRY8uGr71" title="Concentration risk, percentage">33</span>%, and<span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerThreeMember_zbcGppFjuUqd" title="Concentration risk, percentage"> 54</span>% of 2022 revenues were derived from three customers.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Revenues from Films and Licensed Rights</i></b>, are calculated based on expected ultimate revenues estimated over a period not to exceed ten years following the date of initial release of the motion picture. For an episodic television series, the period over which ultimate revenues are estimated cannot exceed ten years following the date of delivery of the first episode, or, if still in production, five years from the date of delivery of the most recent episode, if later. For titles included in acquired libraries, ultimate revenue includes estimates over a period not to exceed twenty years following the date of acquisition.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The cost of services includes only those costs directly related to the services being rendered. For the 2022 period, a majority of the consulting services were performed by the Company’s CEO, Mr. MacGregor, who as described in Note 3 was providing the Company with financing and, as a result, did not receive any separate current or deferred compensation for these services. Due to Mr. MacGregor’s limited annual compensation of $<span id="xdx_907_eus-gaap--DeferredCompensationArrangementWithIndividualCompensationExpense_c20230101__20230630__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zTafCkfmrBjl" title="Annual compensation per month">5,000</span> per month in the first half of 2023 and $<span id="xdx_90D_eus-gaap--DeferredCompensationArrangementWithIndividualCompensationExpense_c20220101__20221231__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zigkW66Wi8rb" title="Annual compensation per month">0</span> in 2022, any allocation of time to these services would have been immaterial. 2022 included $<span id="xdx_909_eus-gaap--CostOfGoodsAndServicesSold_c20220101__20221231__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zni1OhX6oTw5" title="Cost of goods and services">131,722</span> of cost of goods, $<span id="xdx_900_eus-gaap--CostOfGoodsAndServicesSold_c20220101__20221231__srt--OwnershipAxis__custom--BoldCrayonsMember_z6r10fEqKfMk" title="Cost of goods and services">130,000</span> was to Bold Crayon related to CAMA assignment noted above. CAMA agreement income totaled $<span id="xdx_908_eus-gaap--Revenues_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--CashAssetManagementAgreementMember_zOQ9XByO6PGh" title="Revenues">0</span> and $<span id="xdx_90B_eus-gaap--Revenues_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--CashAssetManagementAgreementMember_zppMTMhGRO4a" title="Revenues">249,924</span> for the years ended December 31, 2023 and 2022, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	382900000	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	382900000	shares
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-5000000.0	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-1400000	usd
CY2023	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	178500	usd
CY2023	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	178500	usd
CY2023Q4	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.044	pure
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	72684	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	71684	usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	514000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	195000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	514000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	195000	usd
CY2022	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	68760	usd
CY2023	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	178500	usd
CY2023	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	178500	usd
CY2023Q4	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.044	pure
CY2023	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	178500	usd
CY2023	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	178500	usd
CY2021Q1	APHP	Economic Injury Disaster Loan Noncurrent EconomicInjuryDisasterLoanNoncurrent	149900	usd
CY2021Q1	us-gaap	Debt Instrument Term DebtInstrumentTerm	P30Y
CY2021Q1	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.0375	pure
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	100000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	0	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	65000	usd
CY2023Q4	us-gaap	Deferred Compensation Arrangement With Individual Recorded Liability DeferredCompensationArrangementWithIndividualRecordedLiability	20000	usd
CY2022Q4	us-gaap	Deferred Compensation Arrangement With Individual Recorded Liability DeferredCompensationArrangementWithIndividualRecordedLiability	105000	usd
CY2023Q1	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	105000	usd
CY2023Q1	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	1160221	shares
CY2023Q1	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	0.125
CY2023	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	178500	usd
CY2023	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	178500	usd
CY2023Q4	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.044	pure

Files In Submission

Name	View Source	Status
0001493152-24-011751-index-headers.html	Edgar Link	pending
0001493152-24-011751-index.html	Edgar Link	pending
0001493152-24-011751.txt	Edgar Link	pending
0001493152-24-011751-xbrl.zip	Edgar Link	pending
aphp-20231231.xsd	Edgar Link	pending
aphp-20231231_cal.xml	Edgar Link	unprocessable
aphp-20231231_def.xml	Edgar Link	unprocessable
ex10-1.htm	Edgar Link	pending
ex10-1_001.jpg	Edgar Link	pending
ex10-1_002.jpg	Edgar Link	pending
ex10-1_003.jpg	Edgar Link	pending
ex10-1_004.jpg	Edgar Link	pending
ex10-1_005.jpg	Edgar Link	pending
ex10-1_006.jpg	Edgar Link	pending
ex10-1_1.htm	Edgar Link	pending
ex10-1_1001.jpg	Edgar Link	pending
ex10-1_1002.jpg	Edgar Link	pending
ex10-1_1003.jpg	Edgar Link	pending
ex10-1_1004.jpg	Edgar Link	pending
ex10-1_1005.jpg	Edgar Link	pending
ex10-1_1006.jpg	Edgar Link	pending
ex10-2.htm	Edgar Link	pending
ex10-2_001.jpg	Edgar Link	pending
ex10-2_002.jpg	Edgar Link	pending
ex10-2_003.jpg	Edgar Link	pending
ex10-2_004.jpg	Edgar Link	pending
ex10-2_005.jpg	Edgar Link	pending
ex10-2_006.jpg	Edgar Link	pending
ex10-2_007.jpg	Edgar Link	pending
ex10-2_008.jpg	Edgar Link	pending
ex10-2_009.jpg	Edgar Link	pending
ex10-2_010.jpg	Edgar Link	pending
ex10-2_011.jpg	Edgar Link	pending
ex10-2_012.jpg	Edgar Link	pending
ex10-2_013.jpg	Edgar Link	pending
ex10-2_014.jpg	Edgar Link	pending
ex10-2_015.jpg	Edgar Link	pending
ex10-2_016.jpg	Edgar Link	pending
ex10-2_017.jpg	Edgar Link	pending
ex10-2_018.jpg	Edgar Link	pending
ex10-2_019.jpg	Edgar Link	pending
ex10-3.htm	Edgar Link	pending
ex10-3_001.jpg	Edgar Link	pending
ex10-3_002.jpg	Edgar Link	pending
ex10-3_003.jpg	Edgar Link	pending
ex10-3_004.jpg	Edgar Link	pending
ex10-3_005.jpg	Edgar Link	pending
ex10-3_006.jpg	Edgar Link	pending
ex10-3_007.jpg	Edgar Link	pending
ex10-3_008.jpg	Edgar Link	pending
ex10-3_009.jpg	Edgar Link	pending
ex10-3_010.jpg	Edgar Link	pending
ex10-3_011.jpg	Edgar Link	pending
ex10-3_012.jpg	Edgar Link	pending
ex10-3_013.jpg	Edgar Link	pending
ex10-3_014.jpg	Edgar Link	pending
ex10-3_015.jpg	Edgar Link	pending
ex10-4.htm	Edgar Link	pending
ex10-4_001.jpg	Edgar Link	pending
ex10-4_002.jpg	Edgar Link	pending
ex10-4_003.jpg	Edgar Link	pending
ex10-4_004.jpg	Edgar Link	pending
ex10-4_005.jpg	Edgar Link	pending
ex10-4_006.jpg	Edgar Link	pending
ex10-4_007.jpg	Edgar Link	pending
ex10-4_008.jpg	Edgar Link	pending
ex10-4_009.jpg	Edgar Link	pending
ex10-4_010.jpg	Edgar Link	pending
ex10-4_011.jpg	Edgar Link	pending
ex10-4_012.jpg	Edgar Link	pending
ex10-5.htm	Edgar Link	pending
ex10-5_001.jpg	Edgar Link	pending
ex10-5_002.jpg	Edgar Link	pending
ex10-5_003.jpg	Edgar Link	pending
ex10-5_004.jpg	Edgar Link	pending
ex10-5_005.jpg	Edgar Link	pending
ex10-5_006.jpg	Edgar Link	pending
ex10-5_007.jpg	Edgar Link	pending
ex10-5_008.jpg	Edgar Link	pending
ex10-5_009.jpg	Edgar Link	pending
ex10-5_010.jpg	Edgar Link	pending
ex10-6.htm	Edgar Link	pending
ex10-6_001.jpg	Edgar Link	pending
ex10-6_002.jpg	Edgar Link	pending
ex10-6_1.htm	Edgar Link	pending
ex10-6_1001.jpg	Edgar Link	pending
ex10-6_1002.jpg	Edgar Link	pending
ex10-7.htm	Edgar Link	pending
ex10-7_001.jpg	Edgar Link	pending
ex10-7_002.jpg	Edgar Link	pending
ex10-7_003.jpg	Edgar Link	pending
ex10-7_004.jpg	Edgar Link	pending
ex10-7_005.jpg	Edgar Link	pending
ex10-7_006.jpg	Edgar Link	pending
ex10-7_007.jpg	Edgar Link	pending
ex10-7_008.jpg	Edgar Link	pending
ex10-7_009.jpg	Edgar Link	pending
ex10-7_010.jpg	Edgar Link	pending
ex10-7_011.jpg	Edgar Link	pending
ex10-7_012.jpg	Edgar Link	pending
ex10-8.htm	Edgar Link	pending
ex10-8_001.jpg	Edgar Link	pending
ex10-8_002.jpg	Edgar Link	pending
ex10-8_003.jpg	Edgar Link	pending
ex10-8_004.jpg	Edgar Link	pending
ex10-8_005.jpg	Edgar Link	pending
ex14-1.htm	Edgar Link	pending
ex14-1_001.jpg	Edgar Link	pending
ex14-1_002.jpg	Edgar Link	pending
ex14-1_003.jpg	Edgar Link	pending
ex14-1_004.jpg	Edgar Link	pending
ex14-1_005.jpg	Edgar Link	pending
ex14-2.htm	Edgar Link	pending
ex14-2_001.jpg	Edgar Link	pending
ex14-2_002.jpg	Edgar Link	pending
ex3-1.htm	Edgar Link	pending
ex3-1_001.jpg	Edgar Link	pending
ex3-1_002.jpg	Edgar Link	pending
ex3-1_003.jpg	Edgar Link	pending
ex3-1_004.jpg	Edgar Link	pending
ex3-1_005.jpg	Edgar Link	pending
ex3-1_006.jpg	Edgar Link	pending
ex3-1_007.jpg	Edgar Link	pending
ex3-1_008.jpg	Edgar Link	pending
ex3-2.htm	Edgar Link	pending
ex3-2_001.jpg	Edgar Link	pending
ex3-2_002.jpg	Edgar Link	pending
ex3-2_003.jpg	Edgar Link	pending
ex3-2_004.jpg	Edgar Link	pending
ex3-2_005.jpg	Edgar Link	pending
ex3-2_006.jpg	Edgar Link	pending
ex3-2_007.jpg	Edgar Link	pending
ex3-2_008.jpg	Edgar Link	pending
ex3-2_009.jpg	Edgar Link	pending
ex3-2_010.jpg	Edgar Link	pending
ex3-2_011.jpg	Edgar Link	pending
ex3-2_012.jpg	Edgar Link	pending
ex3-2_013.jpg	Edgar Link	pending
ex3-2_014.jpg	Edgar Link	pending
ex3-2_015.jpg	Edgar Link	pending
ex3-2_016.jpg	Edgar Link	pending
ex3-2_017.jpg	Edgar Link	pending
ex3-3.htm	Edgar Link	pending
ex3-3_001.jpg	Edgar Link	pending
ex3-3_002.jpg	Edgar Link	pending
ex3-3_003.jpg	Edgar Link	pending
ex3-3_004.jpg	Edgar Link	pending
ex3-4.htm	Edgar Link	pending
ex3-4_001.jpg	Edgar Link	pending
ex3-4_002.jpg	Edgar Link	pending
ex3-4_003.jpg	Edgar Link	pending
ex3-4_004.jpg	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
form10-k_htm.xml	Edgar Link	completed
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
aphp-20231231_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
aphp-20231231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$APHP
American Picture House Corp Stock $aphp

2024 Q1 Form 10-K Financial Statement

#000149315224011751 Filed on March 28, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$APHP American Picture House Corp Stock $aphp

2024 Q1 Form 10-K Financial Statement

#000149315224011751 Filed on March 28, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$APHP
American Picture House Corp Stock $aphp